About
Li-Yao Huang holds a DPhil in Biochemistry from Oxford and conducted postdoctoral research at the MRC Weatherall Institute of Molecular Medicine, where he led CRISPR screening projects focused on cancer drug targets. He now leads FinalDose, a YC-backed company working on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
Founder at FinalDoseYC X26
Intro paths
YC
Li-Yao went through Y Combinator (Spring 2026) — any YC alum in your network can reach them through the YC community.
GP
Their group partner at YC was Garry Tan, President & CEO of Y Combinator — the partner who ran FinalDose's batch and knows the company first-hand. YC profile ↗
→
In turn, Li-Yao can intro founders to FinalDose's investors below.
FinalDose's investors · 4
Co-founders at FinalDose
SL
Steven LinFounder
JL
Jeff LiuFounder